Zobrazeno 1 - 5
of 5
pro vyhledávání: '"John R. Ferrarone"'
Autor:
Benjamin D. Stein, John R. Ferrarone, Eric E. Gardner, Jae Won Chang, David Wu, Pablo E. Hollstein, Roger J. Liang, Min Yuan, Qiuying Chen, John S. Coukos, Miriam Sindelar, Bryan Ngo, Steven S. Gross, Reuben J. Shaw, Chen Zhang, John M. Asara, Raymond E. Moellering, Harold Varmus, Lewis C. Cantley
Publikováno v:
Cancer Discovery. 13:1002-1025
KRAS is the most frequently mutated oncogene in human lung adenocarcinomas (hLUAD), and activating mutations frequently co-occur with loss-of-function mutations in TP53 or STK11/LKB1. However, mutation of all three genes is rarely observed in hLUAD,
Autor:
Arun M Unni, Bryant Harbourne, Min Hee Oh, Sophia Wild, John R Ferrarone, William W Lockwood, Harold Varmus
Publikováno v:
eLife, Vol 7 (2018)
Synthetic lethality results when mutant KRAS and EGFR proteins are co-expressed in human lung adenocarcinoma (LUAD) cells, revealing the biological basis for mutual exclusivity of KRAS and EGFR mutations. We have now defined the biochemical events re
Externí odkaz:
https://doaj.org/article/c9a152b7e5fb4105b4de838a7f359c26
Autor:
Lewis C. Cantley, Harold Varmus, Raymond E. Moellering, John M. Asara, Chen Zhang, Reuben J. Shaw, Steven S. Gross, Bryan Ngo, Miriam Sindelar, John S. Coukos, Qiuying Chen, Min Yuan, Roger J. Liang, Pablo E. Hollstein, David Wu, Jae Won Chang, Eric E. Gardner, John R. Ferrarone, Benjamin D. Stein
Figure S7. Tpi1 is required for tumor growth in KP and KPL LUAD models.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::222d1f5d233f06829de0b48c421cb0f7
https://doi.org/10.1158/2159-8290.22553374
https://doi.org/10.1158/2159-8290.22553374
Autor:
Lewis C. Cantley, Harold Varmus, Raymond E. Moellering, John M. Asara, Chen Zhang, Reuben J. Shaw, Steven S. Gross, Bryan Ngo, Miriam Sindelar, John S. Coukos, Qiuying Chen, Min Yuan, Roger J. Liang, Pablo E. Hollstein, David Wu, Jae Won Chang, Eric E. Gardner, John R. Ferrarone, Benjamin D. Stein
KRAS is the most frequently mutated oncogene in human lung adenocarcinomas (hLUAD), and activating mutations frequently co-occur with loss-of-function mutations in TP53 or STK11/LKB1. However, mutation of all three genes is rarely observed in hLUAD,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74a4888ce7db00a4ab236f555bdd0a96
https://doi.org/10.1158/2159-8290.c.6534613.v2
https://doi.org/10.1158/2159-8290.c.6534613.v2
Autor:
Colin P. Tang, Owen Clark, John R. Ferrarone, Carl Campos, Alshad S. Lalani, John D. Chodera, Andrew M. Intlekofer, Olivier Elemento, Ingo K. Mellinghoff
Publikováno v:
Nat Chem Biol
Small-molecule kinase inhibitors represent a major group of cancer therapeutics, but tumor responses are often incomplete. To identify pathways that modulate kinase inhibitor response, we conducted a genome-wide knockout (KO) screen in glioblastoma c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353772edab7f26f780c5777a78c48e8c
https://europepmc.org/articles/PMC9549920/
https://europepmc.org/articles/PMC9549920/